Genetically Modified Specific T cells for COVID-19 Related Disease in Cancer Patients

Inclusion Criteria

• Cancer patients > or = 18 years of age or older.
• English and non-English speaking.
• Cancer patients who have received chemotherapy and have recovered from chemotherapy related adverse events to grade 1 Common Terminology Criteria for Adverse Events (CTCAE).
• Cancer patients need to have COVID-19 related pneumonia with a positive COVID-19 test (bronchoalveolar lavage [BAL], nasal or pharyngeal) and radiological and clinical signs of pneumonia who are hospitalized and have severe illness per National Institutes of Health (NIH) guidelines. Therefore the eligible NIH categories of COVID-19 illness are: * Severe Illness: Individuals who have SpO2 < 94% on room air at sea level, a ratio of arterial partial pressure of oxygen to fraction of inspired oxygen (PaO2/FiO2) < 300 mm Hg, respiratory frequency > 30 breaths/min, or lung infiltrates > 50%. These patients require supplemental oxygen.
• Cancer patients with COVID-19 related pneumonia who have received steroids and remdesivir and continued to require oxygen support. Steroids and remdesivir are the first 2 lines of therapy for COVID-19 CTL according to our institutional guidelines for treatment of COVID-19 disease.
• Written informed consent from patient or designated power of attorney. Patients with cognitive impairment are eligible.
• Subjects are also are required to consent to PA17-0483 for long term follow up per the guidelines set forth by the Food and Drug Administrations' (FDA’s) Biologic Response Modifiers Advisory Committee (BRMAC).
• Negative pregnancy blood test in female patients of childbearing potential, defined as not post-menopausal for 12 months or no previous surgical sterilization. Women of child bearing potential must be willing to use at least two forms of birth control during the study and for at least 6 months after stopping treatment. Acceptable forms of birth control include intrauterine device (IUD), hormonal methods (birth control pills, injections, and implants), condoms, diaphragms, tubal ligation, or vasectomy.

Exclusion Criteria

• Patients who have received anti-thymocyte globulin (ATG) within 14 days or have received donor lymphocyte infusion (DLI), allogeneic stem cell transplantation or campath within 28 days of enrollment.
• Patients with other uncontrolled infections other than COVID19: For bacterial infections, patients must be receiving therapy and have no signs of progressing infection for 72 hours prior to enrollment. For fungal infections patients must be receiving anti-fungal therapy and have no signs of progressing infection for 1 week prior to enrollment. Progressing infection is defined as hemodynamic instability attributable to sepsis or new symptoms, worsening physical signs or radiographic findings attributable to infection. Persisting fever without other signs or symptoms will not be interpreted as progressing infection.
• Active acute graft versus host disease (GVHD) grade > 2.
• Patients with comorbid conditions defined as liver cirrhosis, renal function EGFR < 40 ml/min/1.73m^2, congestive heart failure requiring treatment, history of stroke within 1 year. These comorbidities will be considered exclusion criteria only if they are unrelated to COVID-19 infection since COVID-19 itself can cause multiorgan dysfunction.
• Patients with uncontrolled malignancies. Patients undergoing active chemotherapy